Stock Watch: Wrap Up For The Biotech Winter
A Recovery In Biotech Stocks Has Many False Dawns
Executive Summary
A drastic risk-off pullback in the public market can close an IPO window while private biotechs aspiring for either a public debut or an acquisition by big pharma may be stymied by their stale valuations.